Anti-PD-L1 antibody [28-8] (Ab205921)

Anti-PD-L1 antibody [28-8] (ab205921) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in Flow Cyt, ICC/IF, IHC-Fr, IHC-P, WB, mIHC in human samples. Anti-PD-L1 antibody [28-8] (ab205921) has been cited over 476 times in peer reviewed journals and is trusted by the scientific community. Abcam's high quality manufacturing and validation processes ensure Anti-PD-L1 antibody [28-8] (ab205921) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility. The specificity of Anti-PD-L1 antibody [28-8] (ab205921) has been confirmed by testing in knockout samples. Anti-PD-L1 antibody [28-8] (ab205921) has 13 independent reviews from customers. Anti-PD-L1 antibody [28-8] (ab205921) specifically detects PD-L1 (UniProt ID: Q9NZQ7; Molecular weight: 31kDa) and is sold in a convenient trial size to enable initial testing (20 µL) and larger sizes for subsequent scaling up experiments (50 µL). Conjugation-ready, carrier free format available for antibody clone 28-8 - ab228413. Antibody clone 28-8 is also available pre-conjugated to a variety of labels for your convenience - HRP, PE, Alexa Fluor® 555, Alexa Fluor® 568, Alexa Fluor® 594, FITC ( ab209961, ab209962, ab213358, ab213359, ab213360, ab224027 ). PD-L1 (Programmed Death-Ligand 1) is a protein that plays a significant role in oncology, particularly in the immune response to cancer. It is expressed on the surface of cancer cells and interacts with the PD-1 receptor on T-cells, effectively inhibiting the immune system's ability to attack the tumor. This interaction is a key target for immunotherapy drugs, such as checkpoint inhibitors, which block the PD-1/PD-L1 pathway, allowing the immune system to recognize and destroy cancer cells. FURTHER INFORMATION ON POSITIVE CONTROLS ( Chinese version ) Tissue - Tonsil - with hyperreactive changes. Screening of hyper-reactive tonsils is recommended to find tonsil with the highest expression of PD-L1 in crypt epithelium, macrophages homing the germinal centers and interfollicular mononuclear leukocytes. - Tumor tissues - prescreened for positive tumor and inflammatory infiltrates. PD-L1 expression varies by tumor type so screening is recommended to find positive and negative tumor controls. - The following publication is useful for finding suitable tumor types for PD-L1 expression http://www.immunotherapyofcancer.org/content/1/S1/P53 - Note: Look for specimens with high numbers of inflammatory macrophages and mononuclear leukocytes. Cell Lines - Positive controls: B-CPAP (high), ES-2 (medium), HCC70 (low). Primary antibody negative control: Recombinant Rabbit IgG isotype control antibody, ab172730. Recombinant protein positive control: Recombinant human PD-L1 protein, ab167713. Immunohistochemistry usage For IHC usage on FFPE tissues, we recommend using PD-L1 IHC panel ab236676, which contains PD-L1 antibody clone 28-8 (ab205921), HIER antigen retrieval reagent ( ab208572 ) and IHC detection kit HRP/DAB ( ab209101 ). Western blot usage For clone 28-8, it is recommended to use Odyssey system. This system has the advantages of a wider dynamic range and less background than chemiluminescence. This PD-L1 antibody [28-8] has been used as detector antibody in Human PD-L1 SimpleStep ELISA ® kit: ab214565 and ab277712. To support you in your biomarker discovery and validation studies, we offer a comprehensive suite of solutions including high quality, validated recombinant antibodies and assay kits. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents. What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies.